BioCentury | Oct 3, 2019
Finance
Tenaya to deploy $92M series B to develop heart disease platforms in parallel
...studies as soon as late 2021, CEO Faraz Ali told BioCentury. Nearly three years after Tenaya Therapeutics Inc....
...on a potential listing as well, although Tenaya could raise another private round. Paul Bonanos, Associate Editor Tenaya Therapeutics Inc. heart...
...on a potential listing as well, although Tenaya could raise another private round. Paul Bonanos, Associate Editor Tenaya Therapeutics Inc. heart...